SequelSEC

FEMASYS INC FEMY

Surgical & Medical Instruments & Apparatus · CIK 0001339005 · Fiscal year ends 1231

Revenue
$2.29M
Fiscal year ended 2025-12-31
Operating income
-$17.59M
Fiscal year ended 2025-12-31
Free cash flow
-$19.22M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$29.87MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.49Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue13.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity5.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue22.9%92th
FCF margin-837.9%12th
Operating margin-767.0%12th
Net margin-812.3%12th
R&D / revenue330.4%87th
Revenue YoY growth40.8%82th
SBC / revenue34.5%82th
Current ratio4.53x70th
Gross margin62.0%50th

FEMASYS INC (FEMY) reported revenue of $2.29M and net income of -$18.63M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from FEMASYS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

FEMASYS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$2.29M$1.63M$1.07M$1.21M$1.18M$1.04M
Cost of revenue$872.40K$544.90K$380.07K$441.94K$370.38K$306.53K
Gross profit$1.42M$1.08M$691.90K$764.28K$809.30K$731.38K
Operating income-$17.59M-$17.79M-$14.51M-$11.60M-$8.34M-$6.93M
Net income-$18.63M-$18.82M-$14.25M-$11.39M-$7.54M-$6.91M
Research & development$7.58M$8.22M$7.21M$5.81M$4.08M$4.13M
Weighted-average diluted sharesshares 39.55Mshares 22.27Mshares 15.38Mshares 11.82Mshares 6.71MUnavailable
Pretax income-$18.63M-$18.81M-$14.24M-$11.39M-$7.53M-$6.91M
Income tax expense$1.30K$9.60K$4.34K$6.30K$4.00K$1.80K
Diluted EPS$-0.47$-0.85$-0.93$-0.96$-1.12$-7.20
Selling, general & administrative$11.09M$10.36M$7.51M$5.99M$4.47M$2.85M
General & administrative$6.65M$6.33M$6.86M$5.43M$4.26M$2.54M
Selling & marketing$4.44M$4.03M$650.13K$558.85K$208.74K$310.22K

Balance

FEMASYS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$9.27M$3.45M$21.72M$12.96M$24.78M$3.32M
Total assets$20.72M$12.45M$27.76M$16.90M$28.58M$7.61M
Current assets$16.46M$8.02M$23.18M$14.13M$25.63M$3.86M
Total liabilities$14.85M$10.14M$9.40M$1.65M$2.24M$4.08M
Current liabilities$3.64M$8.58M$3.05M$1.53M$1.69M$2.89M
Total equity incl. NCI$5.87M$2.30M$18.35M$15.24M$26.33M-$51.82M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$55.34M
Inventory$5.74M$3.05M$667.12K$436.72K$208.27K$131.38K
Accounts receivable$616.60K$488.37K$98.91K$77.47K$84.26K$125.79K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.83M$1.42M$1.14M$510.76K$445.52K$674.33K

Cash flow

FEMASYS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$18.69M-$19.44M-$11.28M-$10.73M-$7.93M-$4.93M
Capital expenditures$525.01K$761.71K$143.92K$407.48K$306.87K$8.35K
Investing cash flow-$630.10K-$847.76K-$143.92K-$407.48K-$306.87K$968.32K
Financing cash flow$25.14M$2.03M$20.18M-$681.64K$29.70M$871.65K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$790.14K$444.15K$675.70K$224.94K$193.37K$318.64K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailable$60.75K$229.95K$0UnavailableUnavailable
Depreciation & amortization$342.03K$297.32K$483.48K$561.23K$591.07K$679.65K

Derived

FEMASYS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$19.22M-$20.21M-$11.42M-$11.14M-$8.24M-$4.94M
Gross margin62.0%66.6%64.5%Unavailable68.6%70.5%
Operating margin-767.0%-1091.8%-1353.4%-961.7%-706.7%-668.0%
FCF margin-837.9%-1240.3%-1065.7%-923.5%-698.3%-476.1%
SBC / revenue34.5%27.3%63.0%18.6%16.4%30.7%
Current ratio4.53x0.93x7.59x9.25x15.15x1.34x
Revenue YoY growth40.8%52.0%-11.1%2.2%13.7%Unavailable
Net margin-812.3%-1155.0%-1329.1%-944.6%-639.0%-666.2%
R&D / revenue330.4%504.4%672.5%482.0%346.2%398.0%
CapEx / revenue22.9%46.8%13.4%33.8%26.0%0.8%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FEMY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.